China adds 119 drugs to list

119种药品新纳入医保

China has included 119 more kinds of drugs on its national medical insurance reimbursement¹ list, delivering greater price cuts and benefiting more people, the National Healthcare Security Administration (NHSA) said at a press conference Monday. Ninety-six of the new additions to the list are exclusive drugs that offer lower prices through negotiation² and 16 were newly put on the market this year, the NHSA said.

国家医疗保障局12月28日召开新闻发布会表示，有119种药品新纳入2020年国家医保目录，其中包括谈判调入的96种独家药品和16种今年新上市的药品。这些药品的价格大幅降低，惠及更多群众。

Altogether, a record number of 162 drugs on the list were negotiated for price reduction.

共计有162种药品进行了谈判，为历史最多的一次。

A deal was reached for 119 of the drugs, with their prices dropping an average of 50.64 percent.

最终有119种药品谈判成功，谈判成功的药品平均降价50.64%。

The inclusions also helped expand the scope of reimbursement to cover more diseases, including COVID-19.

此次药品目录调整也有助于扩大报销范围，覆盖了新冠肺炎等多种疾病的用药。

So far, all the medicines listed in China's latest diagnosis³ and treatment plan for COVID-19 have been added to the reimbursement list, the NHSA said.

国家医疗保障局表示，最新版国家新冠肺炎诊疗方案所列药品已被全部纳入。

China currently has 2,800 kinds of medicines on the medical reimbursement list, including 1,374 traditional Chinese patent medicines.

通过本次目录调整，国家医保目录内的药品总数为2800种，其中中成药1374种。